This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

This study has been completed.
Information provided by (Responsible Party):
Adimmune Corporation Identifier:
First received: December 17, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HAI) at three weeks post immunization in non-elderly and elderly subjects in compliance with the requirements of the current European Union (EU) recommendations for the evaluation of the immunogenicity for a new formulation of a licensed flu vaccine (CPMP/BWP/214/96).

Condition Intervention Phase
Influenza Biological: Influenza vaccine (split virion, inactivated) Biological: AdimFlu-S Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Resource links provided by NLM:

Further study details as provided by Adimmune Corporation:

Primary Outcome Measures:
  • Immunogenicity endpoint: Seroprotection rate [ Time Frame: At 3 weeks after vaccination ]
    Seroprotection rate is defined as the proportion of subjects with HAI titer ≥ 1:40.

  • Immunogenicity endpoint: Seroconversion rate [ Time Frame: At 3 weeks after vaccination ]
    The seroconversion is defined as the HAI titer of the post-vaccination serum is at least 1:40 for those who had a negative pre-vaccination HAI serum titer or a four-fold or greater increase in HAI titers in subjects who had a positive pre-vaccination HAI serum titer. The seropositive is defined as the HAI titer ≥ 1:10, and the seronegative is defined as HAI titer < 1:10.

  • Immunogenicity endpoint: Geometric mean folds increase in HAI titer [ Time Frame: At 3 weeks after vaccination ]

Secondary Outcome Measures:
  • Safety: Reactogenicity events [ Time Frame: 7 days after vaccination ]
    Reactogenicity events are pre-specified adverse events systematically recorded for 7 days after vaccination. The selection of the events to be collected systematically is based on events expected to occur with wild-type influenza infection including fever (≥38°C), runny nose or nasal congestion, cough, sore throat, headache, muscle aches, vomiting, nausea and malaise. Furthermore, the local (injection site) reactions will also be evaluated that include soreness/pain, swelling, redness, ecchymosis and limitation of arm motion.

  • Safety: Serious and non-serious adverse events [ Time Frame: Through day 21 post vaccination ]

Enrollment: 130
Study Start Date: August 2012
Study Completion Date: September 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AdimFlu-S Biological: Influenza vaccine (split virion, inactivated)

AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013

Dosage: 0.5mL/per syringe

Administration route: Intramuscular Injection, once

Other Name: AdimFlu-S Influenza Vaccine
Biological: AdimFlu-S


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males or non-pregnant females and aged ≥ 18 years;
  • Willing and able to adhere to visit schedules and all study requirements;
  • Subjects read and signed the study-specific informed consent.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01752881

National Cheng Kung University Hospital
Tainan, Taiwan
Sponsors and Collaborators
Adimmune Corporation
Principal Investigator: Chih-Jen Chang, MD National Cheng-Kung University Hospital
  More Information

Responsible Party: Adimmune Corporation Identifier: NCT01752881     History of Changes
Other Study ID Numbers: FLU12T13A
Study First Received: December 17, 2012
Last Updated: December 17, 2012

Keywords provided by Adimmune Corporation:

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on August 16, 2017